150 related articles for article (PubMed ID: 34692551)
1. Use of
Hou G; Jiang Y; Li F; Cheng X
Front Oncol; 2021; 11():762327. PubMed ID: 34692551
[TBL] [Abstract][Full Text] [Related]
2. Value of fluorine-18-fluorodeoxyglucose PET/CT in localizing the primary lesion in adrenocorticotropic hormone-dependent Cushing syndrome.
Zhou J; Ju H; Zhu L; Pan Y; Lv J; Zhang Y
Nucl Med Commun; 2019 May; 40(5):539-544. PubMed ID: 30973841
[TBL] [Abstract][Full Text] [Related]
3. The value of somatostatin receptor imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing Ectopic ACTH producing tumors.
Özkan ZG; Kuyumcu S; Balköse D; Ozkan B; Aksakal N; Yılmaz E; Sanlı Y; Türkmen C; Aral F; Adalet I
Mol Imaging Radionucl Ther; 2013 Aug; 22(2):49-55. PubMed ID: 24003397
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Impact of [
Wannachalee T; Turcu AF; Bancos I; Habra MA; Avram AM; Chuang HH; Waguespack SG; Auchus RJ
Clin Endocrinol (Oxf); 2019 Aug; 91(2):288-294. PubMed ID: 31066920
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience.
Varlamov E; Hinojosa-Amaya JM; Stack M; Fleseriu M
Pituitary; 2019 Oct; 22(5):445-455. PubMed ID: 31236798
[TBL] [Abstract][Full Text] [Related]
7. ECTOPIC CUSHING SYNDROME: A 10-YEAR EXPERIENCE FROM A TERTIARY CARE CENTER IN SOUTHERN INDIA.
Sathyakumar S; Paul TV; Asha HS; Gnanamuthu BR; Paul MJ; Abraham DT; Rajaratnam S; Thomas N
Endocr Pract; 2017 Aug; 23(8):907-914. PubMed ID: 28614007
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of
Liu Q; Zang J; Yang Y; Ling Q; Wu H; Wang P; Lu L; Zhu Z
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4386-4395. PubMed ID: 34146130
[TBL] [Abstract][Full Text] [Related]
9. Functional imaging in ectopic Cushing syndrome.
Grigoryan S; Avram AM; Turcu AF
Curr Opin Endocrinol Diabetes Obes; 2020 Jun; 27(3):146-154. PubMed ID: 32250975
[TBL] [Abstract][Full Text] [Related]
10. Case Report: A Challenging Localization of a Pulmonary Ectopic ACTH-Secreting Tumor in a Patient With Severe Cushing's Syndrome.
Serban AL; Rosso L; Mendogni P; Cremaschi A; Indirli R; Mantovani B; Rumi M; Castellani M; Chiti A; Croci GA; Mantovani G; Nosotti M; Ferrante E; Arosio M
Front Endocrinol (Lausanne); 2021; 12():687539. PubMed ID: 34305814
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
[TBL] [Abstract][Full Text] [Related]
12. Comparison of (18F)FDG PET/CT and (68Ga)DOTATATE PET/CT imaging methods in terms of detection of histological subtype and related SUVmax values in patients with pulmonary carcinoid tumors.
Komek H; Can C; Urakçi Z; Kepenek F
Nucl Med Commun; 2019 May; 40(5):517-524. PubMed ID: 30694875
[TBL] [Abstract][Full Text] [Related]
13. The role of integrated (18)F-FDG PET/CT in identification of ectopic ACTH secretion tumors.
Xu H; Zhang M; Zhai G; Zhang M; Ning G; Li B
Endocrine; 2009 Dec; 36(3):385-91. PubMed ID: 19806477
[TBL] [Abstract][Full Text] [Related]
14. The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome.
Pacak K; Ilias I; Chen CC; Carrasquillo JA; Whatley M; Nieman LK
J Clin Endocrinol Metab; 2004 May; 89(5):2214-21. PubMed ID: 15126544
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of 68 Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome.
Ding J; Tong A; Hacker M; Feng M; Huo L; Li X
Clin Nucl Med; 2022 Aug; 47(8):669-676. PubMed ID: 35452014
[TBL] [Abstract][Full Text] [Related]
16. Ectopic adrenocorticotropic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing cushing syndrome: a diagnostic dilemma and how to solve it.
Karageorgiadis AS; Papadakis GZ; Biro J; Keil MF; Lyssikatos C; Quezado MM; Merino M; Schrump DS; Kebebew E; Patronas NJ; Hunter MK; Alwazeer MR; Karaviti LP; Balazs AE; Lodish MB; Stratakis CA
J Clin Endocrinol Metab; 2015 Jan; 100(1):141-8. PubMed ID: 25291050
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome.
Tabarin A; Valli N; Chanson P; Bachelot Y; Rohmer V; Bex-Bachellerie V; Catargi B; Roger P; Laurent F
J Clin Endocrinol Metab; 1999 Apr; 84(4):1193-202. PubMed ID: 10199752
[TBL] [Abstract][Full Text] [Related]
18. Characterization of lipid-rich adrenal tumors by FDG PET/CT: Are they hormone-secreting or not?
Takanami K; Kaneta T; Morimoto R; Satoh F; Nakamura Y; Takase K; Takahashi S
Ann Nucl Med; 2014 Feb; 28(2):145-53. PubMed ID: 24272068
[TBL] [Abstract][Full Text] [Related]
19. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
[TBL] [Abstract][Full Text] [Related]
20. Ectopic Adrenocorticotropic Hormone-Secreting Pituitary Adenomas: An Underestimated Entity.
Knappe UJ; Jaspers C; Buschsieweke D; Reinbold WD; Alomari A; Saeger W; Ehlenz K; Mann WA; Kann PH; Feldkamp J
Neurosurgery; 2017 Apr; 80(4):525-533. PubMed ID: 27352274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
